Algeta ASA

For many years, the toxicity associated with the first antibody-drug conjugates (ADCs) kept them away from all but the last lines of treatment for a few hematological cancers. But Gilead Sciences, In

With a number of high-profile exits under its belt, Abingworth has been able to expand its own investor base and raise $315m for ABV VII. The new vehicle is the VC’s 12th fund and means that Abingwort

Although some investors are disappointed by the lack of a straightforward buyout, market analysts agree that Loxo Oncology Inc. achieved victory in multiple ways under an agreement with Bayer AG

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in